Interleukin Gen: (OTC: ILIU)
$0.40
0.00 (0.00%)
Volume 31,540
May 17 03:06 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 0.40 - 0.40 |
| 52wk Low - High | 0.23 - 0.55 |
| Previous Close | 0.40 |
| Avg. Volume | 15,309 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 14.70 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 2.00 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.10 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.10 |
| Current Quarter Estimate | -0.02 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-13-2013 |
| EPS Last Year | -0.12 |
| Expected Earnings Growth | NA |
Company Description
Interleukin Genetics is a biotechnology company focused on developing personalized health products, particularly in regard to modulating the role of inflammation in chronic disease. The company is developing or plans to develop risk assessment tests, pharmacogenetic tests, and nutritional and therapeutic products keyed to genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, periodontal disease, and weight management.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| INTERLEUKIN GEN | ILIU | 0.40 | |
|
| AETERNA ZENTARS | AEZS | 2.10 | |
|
| ANIKA THERAPEUT | ANIK | 14.40 | |
|
| GENTIUM SPA-ADR | GENT | 8.87 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.77 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.33 | |
|
| ALEXION PHARMA | ALXN | 102.90 | |
|
| ALKERMES INC | ALKS | 31.69 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Initial Agreement With Renaissance Health
Mar 04, 2013
ILIU: Excited About PST Test Opportunity
Nov 16, 2012
ILIU: Q2 2012 Results
Aug 16, 2012
ILIU: Positive PST Study Data
Aug 07, 2012
ILIU Scores $3MM In New Financing, Extends Note Maturity
Jul 02, 2012
Report Not Available
Financials
| EPS TTM | -0.12 |
| Sales | 2 |
| Net Income | -5 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | 7.19 |
News
Interleukin Genetics Reports First Quarter 2013 Financial Results - Close-Up Media
May 16, 2013
Interleukin Genetics IncCorporate Event Announcement Notice - Wall Street Horizon
May 14, 2013
Interleukin Genetics Reports First Quarter 2013 Financial Results - Businesswire
May 14, 2013
Interleukin Genetics IncCorporate Event Announcement Notice - Wall Street Horizon
May 11, 2013
Interleukin Genetics IncCorporate Event Announcement Notice - Wall Street Horizon
May 10, 2013
Interleukin Genetics and University of North Carolina Publish Genetic Factors Predictive of Progression of Knee Osteoarthritis - Businesswire
May 8, 2013
Interleukin Genetics IncCorporate Event Announcement Notice - Wall Street Horizon
May 2, 2013
Interleukin Genetics IncCorporate Event Announcement Notice - Wall Street Horizon
May 1, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 1.30 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 36 out of 155 |
